InsiderSignalSign in

← Insider buys

Karah Herdman Parschauer has sold stock and made no open-market buys since May 2018

EVP and Chief Legal Officer at Ultragenyx Pharmaceutical Inc., and 1 other company

SEC CIK 0001677455 · Filings on SEC.gov ↗

$0Bought

$9.5MSold

NoneLast buy

Companies

Every filing

29 filings since May 2018, newest first

Ultragenyx Pharmaceutical Inc.

EVP and Chief Legal Officer

$47K−2.0%Aug 4

Ultragenyx Pharmaceutical Inc.

EVP and Chief Legal Officer

$47K−2.0%Jun 15

Ultragenyx Pharmaceutical Inc.

EVP and General Counsel

$208K−12.0%Mar 10

Ultragenyx Pharmaceutical Inc.

EVP and General Counsel

$185K−10.0%Mar 3

Ultragenyx Pharmaceutical Inc.

EVP and General Counsel

$441K−14.0%Jun 12

Ultragenyx Pharmaceutical Inc.

EVP and General Counsel

$202K−5.0%Mar 5

Evolus, Inc.

Director

$157K−28.0%Feb 2

Ultragenyx Pharmaceutical Inc.

EVP and General Counsel

$197K−8.0%May 5

Ultragenyx Pharmaceutical Inc.

EVP and General Counsel

$143K−5.0%Mar 3

Ultragenyx Pharmaceutical Inc.

EVP and General Counsel

$324K−13.0%Mar 8

Ultragenyx Pharmaceutical Inc.

EVP and General Counsel

$192K−7.0%Mar 3

Ultragenyx Pharmaceutical Inc.

EVP and General Counsel

$25K−1.0%Oct 18

Ultragenyx Pharmaceutical Inc.

EVP and General Counsel

$738K−20.0%Sep 9

Ultragenyx Pharmaceutical Inc.

EVP and General Counsel

$133K−4.0%Jun 11

Ultragenyx Pharmaceutical Inc.

EVP and General Counsel

$36K−1.0%May 10

Ultragenyx Pharmaceutical Inc.

EVP and General Counsel

$549K−12.0%Mar 3

Ultragenyx Pharmaceutical Inc.

EVP and General Counsel

$991K−29.0%Nov 2

Ultragenyx Pharmaceutical Inc.

EVP and General Counsel

$29K−1.0%Oct 16

Ultragenyx Pharmaceutical Inc.

EVP and General Counsel

$950K−29.0%Oct 13

Ultragenyx Pharmaceutical Inc.

EVP and General Counsel

$900K−29.0%Oct 7

Ultragenyx Pharmaceutical Inc.

EVP and General Counsel

$850K−29.0%Sep 24

Ultragenyx Pharmaceutical Inc.

EVP and General Counsel

$1.1M−34.0%Aug 19

Ultragenyx Pharmaceutical Inc.

EVP and General Counsel

$203K−9.0%May 19

Ultragenyx Pharmaceutical Inc.

EVP and General Counsel

$169K−13.0%Jun 24

Ultragenyx Pharmaceutical Inc.

EVP and General Counsel

$32K−2.0%Apr 30

Ultragenyx Pharmaceutical Inc.

EVP and General Counsel

$58K−4.0%Apr 17

Ultragenyx Pharmaceutical Inc.

EVP and General Counsel

$393K−26.0%Oct 9

Ultragenyx Pharmaceutical Inc.

EVP and General Counsel

$101K−8.0%Jun 21

Ultragenyx Pharmaceutical Inc.

EVP and General Counsel

$88K−8.0%May 10

About Karah Herdman Parschauer

Karah Herdman Parschauer is an executive vice president and chief legal officer at Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), where she oversees the company’s legal affairs and serves as a senior member of the executive leadership team.( She has held the executive vice president–level legal role at Ultragenyx since 2016, originally joining the company as Executive Vice President and General Counsel.( In this capacity she supports Ultragenyx’s global rare disease biopharmaceutical business, including securities, corporate governance, compliance, and transactional matters.( Parschauer is a frequent filer on Ultragenyx’s SEC Form 4 insider reports and has executed numerous stock transactions as a reporting insider.(

In addition to her Ultragenyx responsibilities, Parschauer serves as a director of Evolus Inc. (NASDAQ: EOLS), reflecting her broader experience in the life sciences and pharmaceutical sector.( Ownership reports indicate she has been an active corporate insider across several companies, with direct holdings in Ultragenyx and Evolus and historical reporting ties to additional issuers.( Public filings and executive profiles identify her as an individual corporate officer rather than a company, confirming that Parschauer Karah Herdman is a person, not a corporate entity.(

Written by Perplexity from public sources.

Filings come from SEC EDGAR. Not investment advice.